Worth reading
36Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Mixed performance
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Conditional
How definitive the wording is.Contents of this document
Financial results presentationSecond quarter of the fiscal year ending March 20277 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥32,391 million+0.5%
Operating profit¥9 million
Ordinary income¥-145 million
Net income¥-262 million
Selling, general and administrative expensesIncreased due to higher personnel costs and other factors. Amount and SG&A-to-sales ratio: Not disclosed
Full-year earnings forecast
Net Sales
¥68,000 million
Operating profit
¥700 million
Ordinary income
¥400 million
Profit attributable to owners of the parent
¥100 million
What the company explained in this material
Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
Higher revenue from core products in Japan and overseas, increased SG&A due to personnel costs and other factors, and foreign exchange losses and other items. Amount by factor: Not disclosed
Assumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.
US dollar
¥159
Euro
¥182
Singapore dollars
¥124
New initiatives
- Opened a new medical device development site in Kobe
- Established a joint venture in Egypt for the manufacture and sale of blood bags
- New Headquarters Development
- Second JAXA space experiment selection
Segment results
Japan
Net Sales
¥21,715 million-1.0%
Profit
¥297 million-1.2%
Singapore
Net Sales
¥12,443 million+5.9%
Profit
¥-222 million
China
Net Sales
¥2,160 million+4.6%
Profit
¥121 million+40.7%
Philippines
Net Sales
¥1,925 million+16.8%
Profit
¥-332 million
Germany
Net Sales
¥1,857 million-11.0%
Profit
¥201 million-20.6%
Other
Net Sales
¥2,333 million-19.9%
Profit
¥6 million
Medium-term management plan targets
As priority initiatives for the final year of Medium-Term Management Plan 2027, describes accelerating new and growth initiatives, strengthening the earnings base, and expanding earnings from the global business. Numerical targets: Not disclosedOrders received and order backlog
Mentions a recovery in orders, but the amount is Not disclosedNumber of stores and locations
Describes a new medical device development site in Kobe and construction of a new headquarters. Number of stores and openings and closures during the period: Not disclosed| Item | Details |
|---|---|
| Document type | Financial results presentation |
| Fiscal Period Covered | Second quarter of the fiscal year ending March 2027 |
| Net Sales | ¥32,391 million (YoY +0.5%) |
| Operating profit | ¥9 million |
| Ordinary income | ¥-145 million |
| Net income | ¥-262 million |
| Selling, general and administrative expenses | Increased due to higher personnel costs and other factors. Amount and SG&A-to-sales ratio: Not disclosed |
| Full-year earnings forecast | Net Sales ¥68,000 million / Operating profit ¥700 million / Ordinary income ¥400 million / Profit attributable to owners of the parent ¥100 million |
| Segment results | Japan Net Sales ¥21,715 million (YoY -1.0%) / Profit ¥297 million (YoY -1.2%) / Singapore Net Sales ¥12,443 million (YoY +5.9%) / Profit ¥-222 million / China Net Sales ¥2,160 million (YoY +4.6%) / Profit ¥121 million (YoY +40.7%) / Philippines Net Sales ¥1,925 million (YoY +16.8%) / Profit ¥-332 million / Germany Net Sales ¥1,857 million (YoY -11.0%) / Profit ¥201 million (YoY -20.6%) / Other Net Sales ¥2,333 million (YoY -19.9%) / Profit ¥6 million |
| Breakdown of Factors Affecting the Change | Higher revenue from core products in Japan and overseas, increased SG&A due to personnel costs and other factors, and foreign exchange losses and other items. Amount by factor: Not disclosed |
| Number of stores and locations | Describes a new medical device development site in Kobe and construction of a new headquarters. Number of stores and openings and closures during the period: Not disclosed |
| Assumptions Underlying the Business Outlook | US dollar ¥159 / Euro ¥182 / Singapore dollars ¥124 |
| Medium-term management plan targets | As priority initiatives for the final year of Medium-Term Management Plan 2027, describes accelerating new and growth initiatives, strengthening the earnings base, and expanding earnings from the global business. Numerical targets: Not disclosed |
| Orders received and order backlog | Mentions a recovery in orders, but the amount is Not disclosed |
| New initiatives | Opened a new medical device development site in Kobe, Established a joint venture in Egypt for the manufacture and sale of blood bags, New Headquarters Development, Second JAXA space experiment selection |
Items this document does not state (16)
Gross Profit MarginOperating profit marginResults for the three months of the current quarterProgress against full-year forecastSelf-assessment against the planKey KPIsUnit price and quantity metricsNumber of employeesRisk amount incorporated into the outlookFinancial targetsAnnual DividendPayout ratioAcquisition of treasury sharesCapital expendituresMarket Size / ShareKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Revenue increased as growth in domestic closed systems for drug preparation and administration, overseas circuits for component blood donation, and blood bags outweighed the decline in hemodialysis equipment. Operating profit increased as the impact of higher revenue from core products exceeded increases in raw material and personnel costs. Ordinary loss widened because, in addition to higher selling, general and administrative expenses, including personnel costs, the company recorded foreign exchange losses and other items. The downward revision to the full-year profit forecast reflects the expected continued cost burden from the impact of low utilisation through the first half and persistently high raw material prices and other costs.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.